Originally published In Press as doi:10.1074/jbc.M200617200 on February 11, 2002
J. Biol. Chem., Vol. 277, Issue 16, 14135-14145, April 19, 2002
Hypobetalipoproteinemic Mice with a Targeted Apolipoprotein (Apo)
B-27.6-specifying Mutation
IN VIVO EVIDENCE FOR AN IMPORTANT ROLE OF AMINO ACIDS
1254-1744 OF ApoB IN LIPID TRANSPORT AND METABOLISM OF THE
ApoB-CONTAINING LIPOPROTEIN*
Zhouji
Chen
,
Robin L
Fitzgerald, and
Gustav
Schonfeld
From the Division of Atherosclerosis, Nutrition and Lipid Research,
Department of Medicine, Washington University School of Medicine,
St. Louis, Missouri 63110
Received for publication, January 22, 2002, and in revised form, February 5, 2002
 |
ABSTRACT |
Carboxyl-terminal deletion of
apoB-100 may impair its triglyceride (TG)-transporting capability and
alter its catabolism. Here, we compare our newly generated apoB gene
(Apob)-targeted apoB-27.6-bearing mice to our previously
reported apoB-38.9 mice to understand further the relationship between
the size of a truncated apoB variant and its function/metabolism
in vivo. The apoB-27.6-specifying mutation produces a
premature stop codon six amino acids (aa) downstream of the last codon
of mouse Apob exon 24 (corresponding to aa 1254 of human
apoB-100). ApoB-27.6 transcripts were 3- and 5-fold more abundant than
apoB wild type and apoB-38.9 transcripts in the liver. Likewise,
hepatic secretion rates of apoB-27.6 were 7-fold higher than those of
apoB-48 and apoB-38.9. In contrast, apoB-27.6 heterozygotes
(Apob27.6/+) had lower hepatic TG secretion rates
and higher liver TG contents than both apoB-38.9 heterozygotes
(Apob38.9/+) and apoB wild type mice
(Apob+/+). ApoB-27.6 was secreted by
Apob27.6/+ hepatocytes as dense high density
lipoprotein particles. Moreover, despite its high secretion rates,
apoB-27.6 was barely detectable in plasma. Disruption of apoE gene in
Apob38.9/+ and Apob27.6/+
dramatically increased plasma levels of apoB-38.9 as well as apoB-48
but caused no change in plasma apoB-27.6 concentrations. Finally, the
birth rate of apoB-27.6 homozygotes (Apob27.6/27.6)
from intercrosses of Apob27.6/+ was 7-fold lower
than that of Apob38.9/38.9 from
Apob38.9/+ intercrosses (1.8% versus
12%). Crossbreeding of Apob27.6/27.6 and
Apob38.9/38.9 produced viable
Apob27.6/38.9 offspring, but
Apob27.6/27.6 intercrosses produced no offspring.
Together, these results demonstrate in vivo that the
apoB-27.6-apoB-38.9 peptide segment (aa 1254-1744) plays a critical
role, not only in supporting hepatic TG-secretion and in modulating
catabolism of apoB-containing lipoproteins, but also in normal mouse
embryonic development.
 |
INTRODUCTION |
Apolipoprotein (apo)1 B
is the primary structural protein of very low density lipoproteins
(VLDL) and chylomicrons. It plays a crucial role in triglyceride export
by the liver and intestine and in transport of lipids in yolk sacs that
is essential to normal mouse embryonic development (1, 2). The
full-length apoB (apoB-100) contains 4536 amino acids (3) that are
predicted to conform a pentapartite structure composed of three
amphipathic
-helical domains alternating with two
-strand domains
(4). Carboxyl-terminal truncations of apoB-100 resulting from nonsense and frameshift mutations in the apoB gene (Apob) cause
familial hypobetalipoproteinemia (FHBL) in humans, an autosomal
codominant disorder characterized by low levels (<5th percentile) of
plasma apoB and low density lipoprotein (LDL)-cholesterol (5, 6) that
is frequently associated with fatty livers (7-11). Numerous Apob mutations that produce truncated forms of apoB with
predicted sizes ranging from apoB-2 to apoB-89 have been identified in
FHBL subjects (5, 6, 12). ApoB-31 and larger variants of truncated apoB
are detectable at low levels in plasmas of human FHBL subjects, but
truncated apoB variants smaller than apoB-31, such as apoB-29 (13) and
apoB-24 (14), are usually not detectable (5, 6, 12-15). The molecular
mechanism(s) underlying these metabolic derangements is(are) still
poorly understood. An elucidation of these mechanisms may lead to a
better understanding of the structure-function relationship of the apoB molecule.
The production, intravascular metabolism, and clearance of lipoproteins
is a complex process, and plasma levels of truncated apoB-containing
lipoproteins may be low for a variety of reasons. ApoB-89 (16) apoB-75
(17) are produced at slightly lower rates than apoB-100-containing
lipoproteins and are also cleared more rapidly from plasma. These
"large" truncated apoB variants manifest increased affinities for
the LDL receptor and are catabolized primarily in liver (16, 17).
Particles containing "intermediate"-sized variants of truncated
apoB such as apoB-70.5 (18), apoB-54.8 (19), apoB-38.9 (20), or apoB-31
(21) are produced at lower rates than the larger forms of truncated
apoB, but they are not recognized by LDL receptors (22). By analogy to
apoB-48-containing lipoproteins (23), the majority of these particles
probably associates with apoE in plasma and is cleared by liver via LDL receptors and the LDL receptor-related protein, but a large proportion of them is catabolized in the kidney (22, 24), probably mediated by
megalin (22). In contrast, the mechanisms underlying the absence of
"small" truncated apoB variants (<apoB-31) in plasma have not been
elucidated, because a suitable mouse model for such studies is not
available. In fact, despite the availability of several lines of mice
bearing various forms of truncated apoB (25-28), apoB-38.9 (28) is the
smallest variant of truncated apoB produced by those mice reported thus far.
Carboxyl-terminal truncation of apoB also impairs its
triglyceride-transporting capability. We have recently
demonstrated that an apoB-38.9-specifying mutation in mice reduced
hepatic triglyceride secretion rates and caused fatty livers, albeit
rates of apoB-38.9 secretion by the hepatocytes were not altered (28). Kim et al. (27) also reported that the particle volume of
the VLDL produced by the apoB-39-only mice was reduced by 50%,
compared with the VLDL produced by the apoB-48-only mice. Unlike apoB
38.9, truncated apoB variants smaller than apoB-37 are not present in VLDL and circulate at HDL densities in FHBL subjects (21, 29), as do
lipoproteins containing small truncated apoB variants produced by
transfected hepatoma cells (30, 31). Although these earlier studies
suggested that the small variants of truncated apoB had a much smaller
triglyceride-transporting capacity than the larger ones, the in
vivo function of the small truncated apoB variant has not been
adequately studied.
To understand further about the relationship between the size of a
truncated apoB variant and its function/metabolism in vivo, we now report on our new apoB-27.6-bearing FHBL mouse. The availability of our previously reported apoB-38.9-bearing mice (28) and of these
apoB-27.6 mice has permitted the comparison of the metabolism and some
of the functions of these truncated apoB variants with each other and
with the normal variant apoB-48 found in wild type mice. We report on
rates of embryonic production, on the transport of hepatic lipids, on
the hepatic metabolism of apoB in vivo and ex
vivo, and on the differential role of apoE in their clearance. Our
results suggest that the peptide segment of apoB between carboxyl termini of apoB-27.6 and apoB-38.9, namely amino acids (aa) 1254-1744, plays important roles in governing the apoB function and metabolism of
the apoB-containing lipoprotein.
 |
EXPERIMENTAL PROCEDURES |
Production of ApoB-27.6 Mice--
The apoB-27.6 mice were
generated using a clone of homologous recombinant ES cells (clone 83)
(28) bearing a targeted Apob allele in which nucleotide 5449 was deleted and a loxp-PKG-Neo-loxp cassette was inserted
into exon 24 (Fig. 1A). Preparation of the targeting
construct and procedures of ES cell culture and screening of homologous
recombinant clones have been described (28). Briefly, a
replacement-type targeting construct (Fig. 1A) was prepared using a 11.5-kb BglII-BglII genomic fragment
spanning mouse Apob intron 23 through the 5'-end of exon 27 isolated from a BAC clone, which contains a mouse Apob
insert derived from W-4 (129/SvJ) ES cell genomic DNA (clone 12339)
(Genome System, St. Louis, MO). The parental ES cells were derived from
129/SvJ blastocysts (T. J. Ley, Washington University School of
Medicine). After transfection of ES cells with the gel-purified
targeting construct, G418-resistant clones were isolated as described
previously (32) and screened by Southern blotting using a 0.3-kb
HindIII-HpaI genomic fragment (Fig.
1A) as an external probe. The fidelity of the targeted
mutation was confirmed by sequence analysis.
The homologous recombinant ES cells were used for micro-injection
without being subjected to stable transfection with a Cre-recombinase expressing vector. C57BL/6 blastocysts were microinjected with these ES
cells and implanted into pseudopregnant Swiss Webster foster females as
described previously (32) to produce chimeric progeny. Male chimeras
were bred with C57BL/6 females to generate heterozygous apoB-27.6 mice
(apob+/27.6). The apob+/27.6 mice
were intercrossed to create homozygotes
(apob27.6/27.6). They were also bred with
apoB-38.9-only (apob38.9/38.9) mice (28) to generate
apob27.6/38.9 mice. All of the above offspring had a
mixed genetic background with 50% C57BL/6 and 50% 129/SvJ.
In addition, ApoE-null mice (29) (The Jackson Laboratory, Bar Harbor,
ME) were crossbred with either apob+/38.9 (33) or
apob+/27.6 mice. The offspring were intercrossed to
produce apoE-null mice heterozygous for apoB-38.9 or apoB-27.6. The
resultant mice had a mixed genetic background with 75% C57BL/6 and
25% 129/SvJ.
All mice were weaned at 3 weeks of age, housed in a specific-pathogen
free barrier facility with a 12-h light/dark cycle, and fed a regular
mouse chow diet (Ralston Purina, St. Louis, MO).
RNA Analysis--
Total RNA was isolated from mouse livers by a
single-step isolation method using RNAzol B (Tel-Test, Inc.). A
one-tube RT-PCR kit (Roche Biochemicals, Indianapolis, IN) was used for
reverse transcriptase (RT)-PCR using primers corresponding to mouse
Apob exon 22, exon 23, exon 25, various regions of intron
24, or the neomycin-resistant gene Neor
as specified in legends to Fig. 2. The RT-PCR products were
gel-purified and sequenced on an ABI PRISM 377 DNA sequencer (Applied
Biosystems, Foster, CA).
Northern blot analysis was used to determine the size and the levels of
Apob transcripts in the livers of apoB-27.6-producing mice
and their wild type littermates. Thirty micrograms of liver total RNA
pooled from three mice for each apoB genotype was separated by
electrophoresis on a 0.8% agarose-formaldehyde gel and transferred and
immobilized onto a GeneScreen nylon membrane (PerkinElmer Life
Sciences, Boston, MA). A 789-bp fragment of mouse apoB cDNA encoding amino acids 26-289 of mouse apoB (28), which was generated by
RT-PCR using an upstream primer 5'-TACGTGTACAACTATGAAGCT-3' and a
downstream primer 5'-ACGTGGACTTGGTGCTCTC-3', was radiolabeled with
[
-32P]dCTP using a random-primer labeling kit (Roche
Molecular Biochemicals Corp., Indianapolis, IN) and used to probe
Apob transcripts. Northern hybridization was carried out
using Rapid-hyb buffer according to the manufacturer's instruction
(Amersham Biosciences, Inc., Arlington Heights, IL). The blots were
also stripped and probed with a rat
-actin cDNA (Sigma Chemical
Co., St. Louis, MO). The hybridization signals were quantified using
the GS-525 phosphorimaging system (Bio-Rad, Hercules, CA). The
relative apoB mRNA levels are expressed as ratios of apoB
mRNA/
-actin mRNA. Data are presented as mean ± S.D.
(n = 3 measurements).
Western Blot Detection of ApoB and Lipoprotein
Fractionation--
To perform Western blot analysis, mouse plasma (2 µl/well) or liver homogenates (100 µg of protein/well) were
subjected to electrophoresis on 3-12% gradient SDS-PAGE gels under
reducing conditions and electro-transferred onto Immobilon-P (Millipore Corp., Bedford, MA). Western blot analyses were carried out using rabbit anti-mouse apoB antisera (1:10,000) or anti-GST-mouse apoB amino
acids 26-289 (28) and an ECL Western blot detection kit (Amersham
Biosciences, Inc.). The ECL signals were quantified by analyzing the
density of the protein bands on x-ray film using a Sigma gel computer
software (SPPS Science Corp., Chicago, IL).
A fast-performance liquid chromatography (FPLC) Superose column (34)
was used to assess the distribution of lipids and apoB within the
lipoprotein fractions of mouse plasma. The distribution of apoB in each
lipoprotein fraction was determined by Western blot analysis.
Metabolic Labeling and Pulse-chase Studies Using Mouse
Hepatocytes--
Hepatocytes were isolated from 10-week-old mice as
described (28). Viability of the cells was about 80% as determined by Trypan exclusion. Cells were plated onto 6-well plates (0.6 × 106 cells/well) or 100-mm dishes (7 × 106
cells/dish) coated with poly-D-lysine (Sigma Chemical Co.,
St. Louis, MO) and incubated at 37 °C under 5% CO2 in
10% fetal bovine serum (FBS)/Dulbecco's modified Eagle's medium
(DMEM). After 1 h of attachment, the cell monolayers were washed
twice and incubated in 10% FBS/DMEM until used. All experiments
involving cultured hepatocytes were commenced 7-8 h after the cells
were cultured. Following this initial culture period, cells were washed
three times with phosphate-buffered saline and incubated in methionine (Met)- and cysteine (Cys)-free DMEM for 30 min to deplete the cellular
pool of Met and Cys. Thereafter, the medium was replaced with 1 ml of
Met- and Cys-free DMEM containing 200 µCi of 35S-Promix
(530 MBq/ml, Amersham Biosciences, Inc.), an
L-[35S]Met and
L-[35S]Cys metabolic labeling solution, and
cells were labeled for 3 h to determine rates of apoB secretion.
At the end of this incubation period, medium was collected and spun to
remove trace amounts of the cells while the cell monolayers were lysed
in an immunoprecipitation buffer (IP buffer) (150 mM NaCl,
5 mM EDTA, 50 mM Tris, pH 7.4, 0.0625 M sucrose, 0.5% Triton X-100, and 0.5% sodium
deoxycholate). A mixture of protease inhibitors was added to the media
and cell lysates to a final concentration of 1× according to
manufacturer's instruction (Roche Molecular Biochemicals Corp.,
Indianapolis, IN).
Pulse-chase experiments were carried out on the apoB-27.6 heterozygous
hepatocytes to compare the secretion efficiency of apoB-48 and
apoB-27.6. The cells were labeled with 35S-Promix for 45 min as described above. Thereafter, they were washed twice with
phosphate-buffered saline and incubated in 1 ml of DMEM containing 10 mM Met/3 mM Cys for the specified time period.
After the chase incubation, cells and media were processed as described above.
Immunoprecipitation of ApoB--
Immunoprecipitations were used
to quantify the labeled apoB in the cell or secreted into the medium.
For this purpose, 100 µl of 5× IP buffer was added to each tube
containing the conditioned media. Media and cell lysates were incubated
at 4 °C with gentle rotation for 12 h and then were centrifuged
at 10,000 × g for 5 min to remove any unsolubilized
proteins or cell debris. The apoB proteins in the resultant media and
cell lysates were incubated with rabbit anti-mouse apoB antisera for
6-h at 4 °C, and the immunoreaction complex was precipitated with
protein A-agarose (Invitrogen, Grand Island, NY). After washing five
times with 0.5× IP buffer, the immunoprecipitates were dissolved in
SDS-PAGE gel loading buffer and resolved on a 3-12% gradient gel
under reducing conditions. The gels were dried, and the radioactivity associated with apoB was quantified on a GS-525 phosphorimaging system
using a low beta-screen (Bio-Rad).
Density Distribution of the Newly Secreted
ApoB-containing Lipoproteins by Hepatocytes--
To determine the
density distribution of the apoB-containing lipoproteins secreted by
the liver, hepatocytes isolated from apoB-38.9 or apoB-27.6
heterozygotes and from their wild type littermates were continuously
labeled with 35S-Met/Cys for 3 h in 100-mm dishes (4 ml each) as described above but in the presence of 0.5 mM
oleic acids (OA) complexed with bovine serum albumin (ratio of OA to
bovine serum albumin = 3.6:1) (35). The media were then subjected
to density-gradient ultracentrifugation in a d = 1.006-1.25 g/ml KBr density gradient (36, 37). Fractions were
aspirated and dialyzed, thereafter, they were subjected to immunoprecipitation and 35S-labeled apoBs in each fraction
were separated by SDS-PAGE as described above.
Determinations of in Vivo Secretion Rates--
Hepatic secretion
rates of VLDL triglycerides were measured in littermates of
Apob+/+, Apob+/38.9, and
Apob+/27.6 mice (male, 13 weeks old) after
intravenous injection of Triton WR-1339 as described (28). Mice were
fed a fat-free high carbohydrate diet for 12 h prior to the
experiments, and Triton WR-1339 in 100 µl of saline (500 mg/kg of
body weight) was injected into the mice under light aesthesis with
Metophane. Tail vein blood samples were taken at the specified
times after injection for triglyceride measurement.
Quantification of Liver Lipid Contents--
Lipids were
extracted from liver tissues as described previously (38). The dried
lipid extracts were dissolved in 1% Triton X-100 in chloroform and
dried under a stream of N2, and the dried lipid-Triton
X-100 complexes were solubilized in H2O as described (39)
for determination of triglycerides, total cholesterol, and
phospholipids using enzymatic kits (WAKO Chemicals, Inc., Richmond,
VA). The hepatic lipid concentrations were expressed as micrograms of
lipid/mg of protein.
Miscellaneous Procedures--
Cellular protein contents were
determined using a modified Lowry method (40). Student's t
test and analysis of variance were performed to determine the levels of
significance of differences.
 |
RESULTS |
ApoB-27.6-producing Mice--
In our previous study to generate
apoB-38.9 mice (28), the homologous recombinant ES cells were stably
transfected with a Cre cDNA to express Cre to remove the
floxed Neor cassette from the targeted
apoB-38.9-specifying allele (28). This step involved a prolonged
culture period for the targeted ES cells, and it appeared to result in
a low success rate of germ-line transmission. Thus, we wanted to test
whether this step is necessary for our targeting construct in which the
Neor cassette was placed in the middle of an
intron (i.e. intron 24) (Fig.
1A) and presumably, its
retention in the genome may not affect the mRNA expression of the
targeted allele. The parental Apob-targeted ES cells (in
which the Neor cassette was not excised) were
used directly for blastocyst-microinjection without being subjected to
transfection with the Cre expression vector. Two high percentage male
chimeras were produced, and both of them were capable of
germline-transmitting the targeted allele. Unexpectedly, however, the
resultant engineered mice produced an apoB species with a size close to
the previously reported apoB-27.6 (~150 kDa) of FHBL humans (41),
instead of apoB-38.9 (Fig. 1B). Nonetheless, Southern blot
analysis confirmed that the Apob of these mice were
correctly targeted (Fig. 1C).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
Generation of apoB-27.6-bearing mice.
A, gene-targeting strategy. The preparation of the targeting
construct has been described previously (28). It contains a single
nucleotide deletion that leads to production of apoB-38.9. A novel
HpaI restriction site was introduced to the mutation site.
The predicted structure of the targeted Apob allele is also
illustrated (bottom panel). It contained a
Loxp-PKG-Neo-Loxp cassette in intron 24. The external probe
for Southern blot analysis located immediately downstream of the 3'-end
of the targeted segment. B, detection of apoB-27.6 by
Western analysis. Two microliters of mouse plasma were separated on a
3-12% SDS-PAGE gel. Western blotting was carried out using rabbit
anti-mouse apoB polyclonal antibodies as described under
"Experimental Procedures." C, a typical Southern blot
showing hybridization of 32P-labeled external probes to
HpaI digested-genomic DNA from Apob+/+,
Apob+/27.6, Apob27.6/27.6,
Apob+/38.9, and Apob38.9/38.9
mice.
|
|
Characterization of the Targeted Apob Allele mRNA--
The
apoB-27.6 in FHBL humans occurred as a result of a donor splice
mutation of intron 24 (41), leading to formation of a premature-stop
codon 29 residues downstream of the last codon in exon 24 of human
Apob (residue 1254) (42). Based on the similarity between
the sizes of our mouse-truncated apoB variant and the human apoB-27.6,
we suspected that a premature stop codon might have formed near the
3'-end of exon 24. To test this possibility, RT-PCR analysis was
carried out on liver RNA isolated from two mice homozygous for the
targeted allele. The upstream PCR primers corresponded to the 5'-end of
mouse Apob exon 22 or exon 23, which are external to the
targeted construct, whereas the downstream primers tested were chosen
from the following region of the targeted Apob allele: 3'-
and 5'-ends of intron 24 of mouse Apob, 5'-end of
Neor coding region and 5'-end of exon 25 (Fig.
2A). Of the RT-PCR primer
pairs tested, only the exon 22 or exon 23 primer combined with the
Neor primer gave rise to specific RT-PCR
products from the Apob27.6/27.6 liver RNA (920 and
750 bp, respectively) (Fig. 2B). Nucleotide sequencing
analysis of these two PCR products revealed that exon 24 of mouse
Apob and the coding region of Neor
were spliced together (Fig. 2B). This aberrant apoB RNA
splicing lead to formation of a premature-stop codon 6 residues
downstream of the last codon of exon 24 and thus producing a truncated
apoB-27.6 containing a novel 6-amino acid carboxyl-terminal tail (Fig.
2C). Although the formation of this premature stop codon was
an unexpected finding in our current study, it is highly unlikely that
one or more other unexpected modifications had also occurred in the
coding region of this targeted Apob allele, because the
apparent molecular weight of its protein product apoB-27.6 was
consistent with the predicted molecular weight of the protein encoded
by the full-length apoB-27.6 transcript (~150 kDa). Moreover, removal
of the Neor cassette from this allele gave rise
to the expected truncated apoB variant, namely apoB-38.9 (Ref. 28 and
Fig. 1B).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
Characterization of the apoB-27.6
transcript. A, locations and orientations of the
RT-PCR primers. Nucleotide sequences of the primers are as follows:
P1, 5'-TCCAAATGGACTCATCTGCTACAGC-3'; P2,
5'-TCCCTGTGGATCTTTCCCATTATC-3'; P3,
5'-CAGAGTGAGCAGTGTGCTTCTG-3'; P4,
5'-ACCATGATATTCGGCAAGCAGGC-3'; P5,
5'-CACATCCGTGGATACTTGATAAG-3'; P6,
5'-ACCCAAAGGCAAAGGGATGTCAATG-3'. B, agarose-gel
electrophoresis of RT-PCR products. Lanes 1, 3,
and 5 were amplified from apoB-wild type mouse liver RNA;
lanes 2, 4, and 6 were from apoB-27.6
homozygous livers. Primer pairs used for the RT-PCR reactions:
lanes 1 and 2, P1/P6; lanes 3 and
4, P1/P4; lanes 5 and 6, P2/P4. Primer
pairs P1/P3, P1/P5, P2/P3, and P2/P5 did not yield any specific PCR
products (not shown). C, sequence analysis of RT-PCR
products. The DNA fragments corresponding to bands in lanes
1, 4, and 6 of panel B were
purified and sequenced on an ABI PRISM 377 DNA sequencer using the
forward PCR primer P2 as a sequencing primer. The sequence of DNA
template from lane 1 represents the wild type
Apob (Apob+) sequence. Sequences
obtained from the DNA templates of lanes 4 and 6 were identical, and they represent the sequence of the apoB-27.6
(Apob27.6) transcript. The junction between
Apob exon 24 and Neor is indicated by
a red arrow whereas the exon 24-exon 25 junction in the
Apob+ transcript is indicated by a black
arrow. The carboxyl-terminal 6 residues of apoB-27.6 are in
boldface, and the premature stop codon is
underlined.
|
|
Northern analysis of liver RNA using a cDNA probe located near the
5'-end of mouse apoB mRNA (encoding aa 26-289) revealed that there
was only one apoB transcript (7.5 kb) in the apoB-27.6 homozygotes
(Fig. 3). This transcript, but not wild
type apoB- or the apoB-38.9 transcripts, also hybridized to the
Neor cDNA probe (not shown). Together, these
data demonstrated the identity of the 7.5-b transcript as the apoB-27.6
transcript. Quantification of hybridization signal revealed that the
apoB-27.6 transcript was 3-fold more abundant than the wild type
Apob allele transcript (Fig. 3). And, it was 5-fold more
abundant than the apoB-38.9 transcript in livers of
Apob27.6/38.9 mice (Fig. 3). Thus, retention of the
floxed Neor in intron 24 interferes with
normal apoB RNA splicing and the Cre-mediated excision of
Neor is an indispensable step for our
Apob-targeting construct. Nevertheless, this inadvertently
generated apoB-27.6-bearing mouse offered us an excellent opportunity
to understand the functionality of this small variant of truncated
apoB.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 3.
Northern blot analysis. Thirty
micrograms of liver total RNA pooled from three mice for each apoB
genotype (except for ApoB-27.6 homozygotes, n = 2 mice)
were separated in 0.8% agarose-formaldehyde gels. A mouse apoB
cDNA fragment (~ 750 bp) encoding an amino-terminal region
(residues 26-289) of mouse apoB was labeled with 32P and
used for Northern hybridization. The hybridization signals were
quantified by phosphorimaging. The ratios of apoB/ -actin mRNA
are summarized in panel A (mean ± S.D.;
n = 3 determinations); a typical blot is shown in
panel B.
|
|
Inability of ApoB-27.6 to Support Normal Embryonic
Development--
The apoB-27.6-heterozygous offspring developed
normally and were fertile. However, intercrosses of
Apob27.6/+ produced very few viable
Apob27.6/27.6. Of 228 offspring, there were 161 Apob27.6/+, 63 Apob+/+, but only
4 Apob27.6/27.6 mice (Table
I), amounting to only 1.8% of all of the
offspring, which is 6-fold lower than the percentage (12%, Table I) of
Apob38.9/38.9 mice in the offspring produced from
intercrosses of Apob38.9/+ mice. One of the
Apob27.6/27.6 mice died at age of 3 months, but the
other three appeared healthy. Intercrosses of
Apob27.6/27.6 mice produced no offspring, because
all of the fetuses appeared to be reabsorbed during the late stage of
gestation. However, crossbreeding of Apob27.6/27.6
(both males and female) with Apob27.6/+ or
Apob38.9/38.9 mice produced viable
Apob27.6/+ and Apob27.6/38.9
offspring (Table I). The Apob27.6/38.9 mice
developed normally.
View this table:
[in this window]
[in a new window]
|
Table I
Production of viable offspring
The values presented here were based on data obtained from genotyping
of the offspring 2-3 weeks after birth.
|
|
Plasma Lipids and ApoB--
Plasma levels of total cholesterol,
triglycerides, and phospholipids were significantly lower in
Apob27.6/+, Apob27.6/27.6, and
Apob27.6/38.9 mice than in
Apob+/+ mice (Table
II). Plasma total cholesterol levels of
the Apob27.6/27.6 and
Apob27.6/38.9 mice were reduced to 20% of the
Apob+/+ mice.
View this table:
[in this window]
[in a new window]
|
Table II
Plasma lipid concentrations (mg/dl)
Values were obtained from mice (n = 6 except for
apob27.6/27.6 mice (n = 3)) after a
4-h fasting.
|
|
On FPLC analysis, cholesterol peaks corresponding to VLDL (fractions
5-15), LDL (fractions 16-26), and HDL (fractions 27-42) moderately
decreased in the plasmas of apob+/27.6, compared
with wild type mouse plasma (Fig.
4A). All of these lipoprotein
cholesterol peaks dramatically diminished in plasma of
apob27.6/38.9 mice. Western blot analysis of the
FPLC fractions showed that apoB-27.6 was eluted with HDL-sized
particles (fractions 30-38) (Fig. 4D) that are much smaller
than the apoB-38.9 or apoB-48 particles (Fig. 4, B and
C).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4.
Distribution of cholesterol
(A) and the apoB moieties (B-D) in
FPLC-separated lipoprotein fractions of plasma from
Apob+/+ (B),
Apob+/27.6 (C), and
Apob27.6/38.9 (D) mice.
Mouse plasma was fractionated by FPLC, and aliquots of the FPLC
fractions were used for cholesterol determination and Western blot
analysis.
|
|
Based on Western blot analysis using an anti-GST-mouse apoB (aa
26-289) polyclonal antibody (28), plasma apoB-100 and apoB-48 concentrations in Apob27.6/+mice were reduced by 70 and 65%, respectively, compared with those of the wild type mice (Fig.
5A). Furthermore, apoB-27.6
levels in the plasma of apob+/27.6 and
Apob27.6/38.9 mice were only one-tenth and one-fifth
of those of apoB-48 and apoB-38.9, respectively (Fig. 5A).
In contrast, in the liver homogenates, apoB-27.6 levels were 1.5- and
3-fold higher than those of apoB-48 and apoB-38.9 in
apob+/27.6 and Apob27.6/38.9
mice, respectively (Fig. 5B). These opposite trends in
plasma and liver relative levels of apoB-27.6, apoB-38.9, and apoB-48 of these heterozygous mice suggested that either apoB-27.6 was not
secreted as efficiently as apoB-48 and apoB-38.9, or it was cleared
much more rapidly than apoB-48 and apoB-38.9 from the plasma.

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 5.
Relative levels of apoB-100, apoB-48,
apoB-38.9, and apoB-27.6 in the plasma or liver homogenate of apoB wild
type, apoB-38.9, and apoB-27.6 mice. Two microliters of plasma or
100 µg of liver homogenate proteins obtained from mice after a 4-h
fasting was subjected to SDS-PAGE (3-12% gel). Western blot were
carried out using rabbit antisera raised against a GST-mouse apoB (aa
26-289) fusion protein as primary antibodies (Ref. 28). ApoB protein
bands were visualized using an ECL kit. The ECL signals were quantified
as described under "Experimental Procedures." A, each
value represents the mean of three determinations of samples pooled
from four mice for each genotype except for
Apob27.6/27.6 (pooled from two mice). B,
a representative Western blot.
|
|
Hypersecretion of ApoB-27.6--
To compare the secretion
rates of apoB-27.6, apoB-38.9, and apoB-48 by the mouse liver,
cultured primary hepatocytes isolated from Apob+/+,
Apob38.9/+, or Apob27.6/+ mice
were labeled with 35S-Met/Cys for 3 h, and
35S-label radioactivity in intracellular and secreted apoB
variants was quantified (Fig.
6A). As reportedly previously
(28), equal molar amounts of apoB-48 and apoB-38.9 were secreted by the
Apob38.9/+ hepatocytes despite less
35S-labeled apoB-38.9 than 35S-labeled apoB-48
was accumulated inside the cell (Fig. 6A). In contrast, the
relative intensity of the intracellular apoB-27.6 band of
Apob27.6/+ hepatocytes was 1.5-fold stronger than
that of the apoB-48 (Fig. 6A). More importantly, protein
band corresponding to apoB-27.6 in the medium was 5-fold more intensive
than that of apoB-48 (Fig. 6A). These data indicated that,
on the molar bases, the Apob27.6/+ hepatocytes
secreted as much as 7-fold more apoB-27.6 than apoB-48 as the content
of Met and Cys residues in apoB-27.6 is only about 70% of that of
apoB-48 (based on predictions from the human apoB-100 amino acid
sequence). The amounts of apoB-48 secreted by the
Apob38.9/+ or Apob27.6/+ cells
were ~50% of those of the Apob+/+ cells.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 6.
Continuous metabolic labeling and pulsed
chase studies of apoB in cultured hepatocytes. A,
continuous labeling. After a 7-h culture in 10% FBS/DMEM following
isolation, hepatocytes (0.6 × 106) were labeled with
35S-Promix for 180 min in Met- and Cys-free DMEM. ApoB
proteins in the cell lysate or the medium were immunoprecipitated and
resolved on SDS-PAGE (3-12% gel) and quantified using
phosphorimaging. The intensities of signals were expressed as arbitrary
units (above the gel). B, pulse-chase studies of
Apob27.6/+ hepatocytes. Hepatocytes were prepared
and labeled for 45 min as described in panel A. Thereafter
they were chased for the indicated time periods. After
immunoprecipitation and separation on SDS-PAGE, the apoB bands were
quantified by phosphorimaging. The lower panel showed a
typical gel image that was overexposed to visualize apoB-100.
|
|
Pulse-chase studies of Apob27.6/+ hepatocytes
revealed that apoB-27.6 was secreted at faster rates and much more
efficiently that apoB-48 and apoB-100 from the same cells (Fig.
6B). Thus, the high synthetic rate and the high secretion
efficiency of apoB-27.6 both may contribute to the hypersecretion of
this truncated variant by the Apob27.6/+ hepatocytes.
To compare the lipid-transporting capacities of apoB-27.6, apoB-38.9,
and apoB-48 in our mice, the hepatocytes were labeled with
[35S]methionine/cysteine for 4 h in the presence of
OA (0.5 mM), and the conditioned media were subjected to
density-gradient ultracentrifugation. As shown in Fig.
7, ~50% of apoB-48 were secreted as
VLDL by hepatocytes of all three Apob genotypes. There were
small amounts of apoB-38.9 secreted as VLDL by the
Apob38.9/+ hepatocytes, but the majority of
apoB-38.9 was secreted as lipoproteins with LDL/HDL densities. In
contrast, no apoB-27.6 was detected in VLDL or LDL in the conditioned
medium of Apob27.6/+ hepatocytes. Almost all of the
apoB-27.6 secreted was distributed at the upper limit of HDL densities,
i.e. >1.15 g/ml. Again, near equal amounts of apoB-48 and
apoB-38.9 were secreted by the Apob38.9/+
hepatocytes whereas 6- to 7-fold more apoB-27.6 than apoB-48 was
secreted by the Apob27.6/+ hepatocytes. Only small
amounts of 35S-apoB-100 were seen, and they all floated
with VLDL densities (Fig. 7).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 7.
Density distribution of
apoB-containing lipoproteins secreted by cultured
Apob+/+, Apob38.9/+,
or Apob27.6/+ hepatocytes. Conditioned
media from 100-mm dishes after a 4-h labeling in the presence of 0.5 mM oleic acids were subjected to ultracentrifugation in a
d = 1.006-1.25 g/ml KBr density gradient. Fractions (1 ml each) were dialyzed, and the apoBs were immunoprecipitated and
separated on SDS-PAGE (3-12%).
|
|
Impaired Hepatic Triglyceride Secretion and Fatty Livers in the
ApoB-27.6-bearing Mice--
The in vivo triglyceride
secretion rates by livers of Apob38.9/+,
Apob27.6/+, and Apob+/+ mice were
determined using Triton-WR1339 as inhibitor for VLDL lipolysis.
ApoB-38.9 mutation caused a 35% reduction in hepatic triglyceride
secretion rates in Apob38.9/+ mice, whereas the
apoB-27.6 mutation produced a 45% decrease in
Apob27.6/+ mice (Fig.
8A). Thus, high secretion
rates of apoB-27.6 did not offset the inability of apoB-27.6 to
transport triglycerides. Due to the lower VLDL-triglyceride secretion
rates by the Apob27.6/+ mouse liver, the
Apob27.6/+ mice accumulated more triglycerides in
their livers than the Apob38.9/+ mice (Fig.
8B). A much more severe fatty liver occurred in the Apob27.6/38.9 and Apob27.6/27.6
mice (data not shown).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 8.
Hepatic triglyceride secretion rates and
liver lipid contents of Apob+/+,
Apob38.9/+, or
Apob27.6/+ mice. A, plasma
triglyceride accumulation after injection of Triton WR-1339.
Apob+/+ (WT),
Apob+/38.9 (B38.9-Het.), and
Apob27.6/+ (B27.6-Het.) mice were fed a
fat-free, high carbohydrate diet for 8 h and injected with Triton
WR-1339. Blood samples were taken at the indicated time points. Plasma
triglyceride concentrations were determined. The values obtained within
30 s after injection were treated as baseline values and
subtracted from values obtained at later time points. Each data point
represents mean ± S.D. (n = 4 animals). B,
hepatic lipid contents of Apob+/+ (WT),
Apob+/38.9 (Het.-B38.9),
Apob+/27.6 (Het.-B27.6) mice. Lipids were
extracted from livers and assayed for contents of triglycerides,
phospholipids, and total cholesterol. Lipid levels are presented as
milligrams/g of liver protein. Each data point represents mean ± S.D. (n = 6). **, significantly different from the WT
values (p < 0.01).
|
|
ApoE Is Not Involved in Rapid Catabolism of Lp-B-27.6--
The
high production rates of apoB-27.6 by the hepatocytes and the low
levels of apoB-27.6 in the plasma combined strongly suggested that the
apoB-27.6-containing lipoproteins were cleared from the plasma very
rapidly. To determine if apoE plays a role in catabolism of these
lipoproteins, Apob27.6/+ mice were crossbred with
apoE knockout mice to disrupt the apoE gene (Apoe). Viable
Apoe
/
/Apob27.6/+ mice
were produced. Disruption of Apoe increased plasma apoB-48 levels in Apob+/+, Apob27.6/+,
and Apob38.9/+ mice by 10- to 15-fold (Fig.
9). It also resulted in a 5-fold increase
in plasma apoB-38.9 levels in Apob38.9/+. In
contrast, the absence of Apoe function caused no change in plasma levels of apoB-27.6 in the apoB-27.6 heterozygous mice (Fig. 9),
indicating that catabolism of Lp-B-27.6 is apoE-independent.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 9.
Western blot analysis of apoB in apoB-38.9
and apoB-27.6 mice in apoE wild type or apoE-null background.
Plasma was sampled from 8-week-old mice after fasting for 4 h. A
Western blot was performed as described under "Experimental
Procedures." Each lane represents plasma samples pooled
from three mice of each genotype. The experiment was repeated three
times, and similar results were obtained.
|
|
 |
DISCUSSION |
The ApoB-27.6-bearing FHBL Mouse Model--
The apoB-27.6 mouse
described herein contains a premature-stop codon 6 amino acid residues
downstream from residue 1254 of apoB-100. Compared with the previously
reported apoB-27.6 in FHBL subjects that contain a novel peptide of 29 residues at the carboxyl terminus (41, 42), the apoB-27.6 produced by
our mice more faithfully represents the amino-terminal 27.6% of
apoB-100. Furthermore, of much value for our studies, the abundance of
apoB-27.6 mRNA was considerably higher than that of the wild type
allele in the livers of our Apob27.6/+ mice, and of
the previously reported apoB-gene-targeted mice (25-28). Such an
elevated level of apoB-27.6 mRNA may be due to the presence of the
Neo-resistant gene mRNA in the 3'-untranslated region of the
apoB-27.6 transcript and thus it may not reflect the apoB-27.6 mRNA
levels in FHBL humans. Nevertheless, the high hepatic apoB-27.6
mRNA levels lead to augmented synthetic and secretion rates of
apoB-27.6 by the hepatocytes of apoB-27.6-bearing mice. Consistent with
our results, high levels of hepatic apoB mRNA, such as those
occurring in the Apob transgenic mice (43), have been shown
to be capable of inducing apoB secretion in vivo, although
physiological regulation of apoB secretion occurs mainly at the
post-transcriptional levels (44). The availability of our "high
apoB-27.6-producer" mice enabled us to study the function and
metabolism of apoB-27.6 in vivo.
Inability of ApoB-27.6 to Support Embryogenesis--
ApoB is
required in the transport of lipids in the yolk sac; in the absence of
apoB-containing lipoproteins embryonic development of the central
nervous system in mice is grossly deformed, resulting in fetal losses
(1, 2). The rates of fetal production of Apob27.6/27.6 mice resembles those of apoB
/
null mice (1), suggesting that apoB-27.6 is nearly as
deficient in the transport of placental nutrient lipids and in
supporting embryonic development as is the absence of apoB. The
specific nutrient deficiencies responsible for the fetal wastage remain to be determined. By contrast, yields of
Apob38.9/38.9 offspring are nearly half of expected
and yields of apoB27.6/38.9 offspring are similar to those of
apoB38.9/38.9, suggesting that the peptide segment between
carboxyl termini of apoB-27.6 and apoB-38.9 is critical for embryonic development.
Reduced Ability of ApoB-27.6 to Export Triglycerides in the
Liver--
The apoB-27.6-apoB-38.9 peptide segment is also important
in the export of triglycerides from the liver. In comparison with Apob+/+ mice, Apob38.9/+ mice
secrete triglycerides at a lower rate into plasma in vivo and accumulate more triglycerides in their livers.
Apob27.6/+ mice secrete at an even slower rate and
accumulate more triglycerides, despite the high secretion rates of
apoB-27.6 protein. These in vivo results are compatible with
the notion derived from cell culture experiments that the ability of a
carboxyl-terminally truncated form of apoB to transport triglycerides
is positively correlated with its size (30, 31). In addition, a
previous study (45) on transfected hepatoma cells has suggested that the apoB-29-apoB-34 peptide segment may have a critical role in mediating apoB-48-VLDL assembly. Our current study tends to provide in vivo evidence supporting this observation. However, more
studies are required to define further the domain(s) within the
apoB-27.6-apoB-38.9 segment that may have a particularly important role
in determining the lipid-transporting capability of the apoB molecule.
Clearance of ApoB-27.6-containing Lipoproteins and the Role of
ApoE--
Although the synthesis and secretion rates of apoB-27.6 in
our Apob27.6/+ mice were several times
higher than those of apoB-100 and apoB-48, apoB-27.6 was
present in the plasma at 8-fold lower concentrations than
apoB-48 or apoB-100. Similarly, even though the mRNA levels and
hepatocellular contents of apoB-27.6 were much higher than those of
apoB-38.9, plasma levels of apoB-38.9 were 5-fold higher than those of
apoB-27.6 in the Apob27.6/38.9 mice. Together, these
findings strongly suggest that apoB-27.6-containing particles were
cleared from the plasma at much faster rates than the apoB-100-,
apoB-48-, or apoB-38.9-containing lipoproteins. Moreover, our finding
that disruption of Apoe did not cause accumulation of
apoB-27.6 in plasma demonstrates that one or more catabolic pathways of
apoB-27.6 particles are fundamentally differently from that of apoB-48
particles in which apoE plays a crucial role (23). Unlike apoB-27.6,
plasma levels of apoB-38.9 were augmented in response to disruption of
Apoe, albeit to a much lesser extent than the apoB-48. Thus,
deleting the carboxyl-terminal 490 amino acids of apoB-38.9 may
severely impair the ability of the resultant truncated apoB-containing
lipoproteins to recruit apoE but still greatly accelerates clearance of
these lipoproteins from plasma. Variants of truncated apoB smaller than
apoB-31 are not detectable in FHBL humans (12-15). The results of our
present study provide strong evidence that accelerated clearance rates
may be responsible for the absence of small truncated apoB variants in
FHBL humans, probably via an apoE-independent mechanism.
Due to the low plasma levels of apoB-27.6-containing lipoproteins and
the inviability of apoB-27.6 homozygous mice, we have not been able to
isolate these lipoproteins from our mice to determine their fractional
catabolic rates directly nor study the tissue loci of their catabolism
or their cellular catabolic pathway(s). Using other truncated
apoB-containing lipoproteins isolated from FHBL humans, we have
previously shown that these lipoproteins are cleared from the plasma
faster than the normal apoB-100-containing LDL (22, 24). Renal uptake
via the proximal tubular endocytic receptor megalin was identified as a
major mechanism underlying the accelerated catabolism of these
lipoproteins (22). We have localized a megalin-binding site within the
amino-terminal 15% of human apoB-100 (46). Thus, it is entirely
possible that the renal megalin-mediated pathway is also an important
pathway for catabolism of the apoB-27.6-containing particles. The
molecular size and/or the shape of a plasma protein are important
determinants in its renal glomerular permeability. The circulating
mouse apoB-27.6 lipoproteins were much smaller than apoB-100-,
apoB-48-, or apoB-38.9-containing lipoproteins. This may explain why
apoB-27.6 and, presumably, other small variants of truncated apoB were
metabolized faster than the latter. However, there may be one or more
other mechanisms involved in uptake of the lipoproteins containing
small variants of truncated apoB. For example, a study by Kreuzer
et al. (47) indicated that a peptide segment within the
amino-terminal 23% of apoB-100 could be recognized by a
macrophage-scavenger receptor without oxidative modification of the
protein. This scavenger receptor-recognition site appeared to be
inactive in the native apoB-48- or apoB-100-containing lipoproteins
(47) but could be active in the unmodified small truncated
apoB-containing lipoproteins. Further studies are required to elucidate
the relative importance of particle sizes, apoE recognition, or other
factors in determining the differing rates of clearance of apoB-27.6
and apoB-38.9 lipoprotein particles.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants R37 HL-424460 and RO1 HL-59515 and by funds from the General Clinical Research Center (GCRC-5 MO1RR0036), Diabetes Research Training
Center (5P60DK20579), Clinical Nutrition Research Unit (P30DK56341),
Digestive Disease Center (1P30DK52574), and Siteman Cancer Center
(1P30CA91842-01) at Washington University School of Medicine.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Division of
Atherosclerosis, Nutrition and Lipid Research, Dept. of Medicine, Washington University School of Medicine, Box 8046, 660 S. Euclid Ave.,
St. Louis, MO 63110. Tel.: 314-747-4352; Fax: 314-362-3513; E-mail:
zchen@im.wustl.edu.
Published, JBC Papers in Press, February 11, 2002, DOI 10.1074/jbc.M200617200
 |
ABBREVIATIONS |
The abbreviations used are:
apo, apolipoprotein;
VLDL, very low density lipoprotein;
LDL, low density lipoprotein;
HDL, high density lipoprotein;
FHBL, familial hypobetalipoproteinemia;
ES, embryonic stem;
aa, amino acid(s);
FPLC, fast performance liquid
chromatography;
RT, reverse transcription;
IP, immunoprecipitation;
OA, oleic acids;
FBS, fetal bovine serum;
DMEM, Dulbecco's modified
Eagle's medium;
GST, glutathione S-transferase.
 |
REFERENCES |
| 1.
|
Farese, R. V., Jr.,
Ruland, S. L.,
Flynn, L. M.,
Stokowski, R. P.,
and Young, S. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1774-1778[Abstract/Free Full Text]
|
| 2.
|
Rabbe, M.,
Flynn, L. M.,
Zlot, C. H.,
Wong, J. S.,
Veniant, M. M.,
Hamilton, R. L.,
and Young, S. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8686-8691[Abstract/Free Full Text]
|
| 3.
|
Knott, J.,
Pease, R. J.,
Powell, L. M.,
Wallis, S. C.,
Rall, S. C., Jr.,
Innerarity, T. L.,
Blackhart, B.,
Taylor, W. H.,
Marcel, Y. L.,
Milne, R.,
Johnson, D.,
Fuller, M.,
Lusis, A. J.,
McCarthy, B. J.,
Mahley, R. W.,
Levy-Wilson, B.,
and Scott, J.
(1986)
Nature
323,
734-738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Segrest, J. P.,
Jones, M. K.,
Loof, H. D.,
and Dashti, N.
(2001)
J. Lipid Res.
42,
1346-1367[Abstract/Free Full Text]
|
| 5.
|
Linton, M. F.,
Farese, R. V., Jr.,
and Young, S. G.
(1993)
J. Lipid Res.
34,
521-541[Medline]
[Order article via Infotrieve]
|
| 6.
|
Schonfeld, G.
(1995)
Annu. Rev. Nutr.
15,
23-34[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Tarugi, P.,
Lonardo, A.,
Ballarini, G.,
Grisendi, A.,
Pulvirenti, M.,
Bagni, A.,
and Calandra, S.
(1996)
Gastroenterology
111,
1125-1133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Ogata, H.,
Akagi, K.,
Baba, M.,
Nagamatsu, A.,
Suzuki, N.,
Nomiyama, K.,
and Fujishima, M.
(1997)
Am. J. Gastroenterol.
92,
339-342[Medline]
[Order article via Infotrieve]
|
| 9.
|
Castellano, G.,
Garfia, C.,
Gomez-Coronado, D.,
Arenas, J.,
Manzanares, J.,
Colina, F.,
and Solis-Herruzo, J. A.
(1997)
J. Clin. Gastroenterol.
25,
379-382[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Schonfeld, G.,
Ackerman, J.,
and Yablonskiy, D.
(2001)
Arterioscler. Thromb. Vasc. Biol.
21,
656 (Abstract)
|
| 11.
|
Tarugi, P.,
Lonardo, A.,
Gabelli, C.,
Sala, F.,
Ballarini, G.,
Cortella, I.,
Previato, L.,
Bertolini, S.,
Cordera, R.,
and Calandra, S.
(2001)
J. Lipid Res.
42,
1552-1561[Abstract/Free Full Text]
|
| 12.
|
Wu, J.,
Kim, J., Li, Q.,
Kwok, P.-Y.,
Cole, T. G.,
Cefalu, B.,
Averna, M.,
and Schonfeld, G.
(1999)
J. Lipid Res.
40,
955-959[Abstract/Free Full Text]
|
| 13.
|
Collins, D. R.,
Knott, T. J.,
Pease, R. J.,
Powell, L. M.,
Wallis, S. C.,
Robertson, S.,
Pullinger, C. R.,
Milne, R. W.,
Marcel, Y. L.,
Humpheries, S. E.,
Talmud, P. J.,
Lloyd, J. K.,
Miller, N. E.,
Muller, D.,
and Scott, J.
(1988)
Nucleic Acids Res.
16,
8361-8375[Abstract/Free Full Text]
|
| 14.
|
Huang, L.-S.,
Ripps, M. E.,
Korman, S. H.,
Deckelbaum, R. J.,
and Breslow, J. L.
(1989)
J. Biol. Chem.
264,
11394-11400[Abstract/Free Full Text]
|
| 15.
|
Huang, L.-S.,
Kayden, H.,
Sokol, R. J.,
and Breslow, J. L.
(1991)
J. Lipid Res.
32,
1341-1348[Abstract]
|
| 16.
|
Parhofer, K. G.,
Barrett, P. H.,
Bier, D. M.,
and Schonfeld, G.
(1992)
J. Clin. Invest.
89,
1931-1937[Medline]
[Order article via Infotrieve]
|
| 17.
|
Krul, E. S.,
Parhofer, K. G.,
Barrett, P. H. R.,
Wagner, R. D.,
and Schonfeld, G.
(1992)
J. Lipid Res.
33,
1037-1050[Abstract]
|
| 18.
|
Groenewegen, W. A.,
Krul, E. S.,
Averna, M. R.,
Pulai, J.,
and Schonfeld, G.
(1994)
Arteriolscler. Thromb.
14,
1695-1704[Abstract/Free Full Text]
|
| 19.
|
Wagner, R. D.,
Krul, E. S.,
Tang, J.,
Parhofer, K. G.,
Garlock, K.,
Talmud, P.,
and Schonfeld, G.
(1991)
J. Lipid Res.
32,
1001-1011[Abstract]
|
| 20.
|
Groenewegen, W. A.,
Averna, M. R.,
Pulai, J.,
Krul, E. S.,
and Schonfeld, G.
(1994)
J. Lipid Res.
35,
1012-1025[Abstract]
|
| 21.
|
Young, S. G.,
Hubl, S. T.,
Smith, R. S.,
Snyder, S. M.,
and Terdiman, J. F.
(1990)
J. Clin. Invest.
85,
933-942[Medline]
[Order article via Infotrieve]
|
| 22.
|
Chen, Z.,
Saffitz, J. E.,
Latour, M. A.,
and Schonfeld, G.
(1999)
J. Clin. Invest.
103,
1419-1430[Medline]
[Order article via Infotrieve]
|
| 23.
|
Cooper, A. D.
(1997)
J. Lipid Res.
38,
2173-2192[Abstract]
|
| 24.
|
Zhu, X.,
Noto, D.,
Seip, R.,
Shaish, A.,
and Schonfeld, G.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
1032-1038[Abstract/Free Full Text]
|
| 25.
|
Homanics, G. E.,
Smith, T. J.,
Zhang, S. H.,
Lee, D.,
Young, S. G.,
and Maeda, N.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2389-2393[Abstract/Free Full Text]
|
| 26.
|
Kim, E.,
Cham, C. M.,
Veniant, M. M.,
Ambroziak, P.,
and Young, S. G.
(1998)
J. Clin. Invest.
101,
1468-1477[Medline]
[Order article via Infotrieve]
|
| 27.
|
Kim, E.,
Ambroziak, P.,
Veniant, C. M.,
Hamilton, R. L.,
and Young, S. G.
(1998)
J. Biol. Chem.
273,
33977-33984[Abstract/Free Full Text]
|
| 28.
|
Chen, Z.,
Fitzgerald, R. L.,
Averna, M. R.,
and Schonfeld, G.
(2000)
J. Biol. Chem.
275,
32807-32815[Abstract/Free Full Text]
|
| 29.
|
McCormick, S. P. A.,
Day, W. A.,
and George, P. M.
(1995)
Biochim. Biophys. Acta
1258,
49-56[Medline]
[Order article via Infotrieve]
|
| 30.
|
Yao, Z.,
Blackhart, B. D.,
Linton, M. F.,
Taylor, S. M.,
Young, S. G.,
and McCarthy, B. J.
(1991)
J. Biol. Chem.
266,
3300-3308[Abstract/Free Full Text]
|
| 31.
|
Graham, D. L.,
Knott, T. J.,
Jones, T. C.,
Pease, R. J.,
Pullinger, C. R.,
and Scott, J.
(1991)
Biochemistry
30,
5616-5621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Hug, B. A.,
Wesselschmidt, R. L.,
Fiering, S.,
Bender, M. A.,
Epner, E.,
Groudine, M.,
and Ley, T. J.
(1996)
Mol. Cell. Biol.
16,
2906-2912[Abstract]
|
| 33.
|
Piedrahita, J. A,
Zhang, S. H.,
Hagaman, J. R.,
Oliver, P. M.,
and Maeda, N.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4471-4475[Abstract/Free Full Text]
|
| 34.
|
Jiao, S.,
Cole, T. G.,
Kitchens, R. T.,
Pfleger, B. A.,
and Schonfeld, G.
(1990)
J. Lipid Res.
31,
467-477[Abstract]
|
| 35.
|
Dixon, J. L.,
Furukawa, S.,
and Ginsberg, H. N.
(1991)
J. Biol. Chem.
266,
5080-5086[Abstract/Free Full Text]
|
| 36.
|
Van Greevenbroek, M. M. J.,
Voorhout, W. F.,
Erkelens, D. W.,
and De Bruin, T. W. A.
(1995)
J. Lipid Res.
36,
13-24[Abstract]
|
| 37.
|
Redgrave, T. G.,
Roberts, D. C. K.,
and West, C. E.
(1975)
Anal. Biochem.
65,
42-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Bligh, E. G.,
and Dyer, W. J.
(1959)
J. Biochem. Physiol.
31,
911-917
|
| 39.
|
Carr, T. P.,
Anderson, C. J.,
and Rudel, L. L.
(1993)
Clinic. Biochem.
26,
39-42
|
| 40.
|
Marwell, M. A.,
Hass, S. M.,
Bieber, L. L.,
and Tolbert, N. E.
(1978)
Anal. Biochem.
87,
206-210[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Talmud, P. J.,
Krul, E. S.,
Pessah, M.,
Gay, G.,
Schonfeld, G.,
Humphries, S. E.,
and Infante, R.
(1994)
J. Lipid Res.
35,
468-477[Abstract]
|
| 42.
|
Nemeth-Slany, A.,
Talmud, P.,
Grundy, S. M.,
and Patel, S. B.
(1997)
Atherosclerosis
133,
163-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Kim, E.,
and Young, S. G.
(1998)
J. Lipid Res.
39,
703-723[Abstract/Free Full Text]
|
| 44.
|
Davis, R. A.
(1999)
Biochim. Biophys. Acta
1440,
1-31[Medline]
[Order article via Infotrieve]
|
| 45.
|
McLeod, R. S.,
Wang, Y.,
Wang, S.,
Rusiñol, A.,
Links, P.,
and Yao, Z.
(1996)
J. Biol. Chem.
271,
18445-18455[Abstract/Free Full Text]
|
| 46.
|
Chen, Z.,
and Schonfeld, G.
(1999)
Circulation
100, (suppl.),
I-329
|
| 47.
|
Kreuzer, J.,
White, A. L.,
Knott, T. J.,
Jien, M. L.,
Mehrabian, M.,
Scott, J.,
Young, S. G.,
and Haberland, M. E.
(1997)
J. Lipi Res.
38,
324-342
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea